References
- Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–387. doi:10.1016/j.ejca.2018.07.005.
- Cho WC, Yip TT, Cheng WW, Au JS. Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis. Br J Cancer. 2010;102(12):1731–1735. doi:10.1038/sj.bjc.6605700.
- Li XF, Ma Y. Preclinical visualization of hypoxia, proliferation and glucose metabolism in non-small cell lung cancer and its metastasis. Boston (MA): Springer; 2014.
- Giatromanolaki A, Sivridis E, Arelaki S, Koukourakis MI. Expression of enzymes related to glucose metabolism in non-small cell lung cancer and prognosis. Exp Lung Res. 2017;43(4–5):167–174. doi:10.1080/01902148.2017.1328714.
- Sanchez JG, Okreglicka K, Chandrasekaran V, Welker JM, Sundquist WI, Pornillos O. The tripartite motif coiled-coil is an elongated antiparallel hairpin dimer. Proc Natl Acad Sci U S A. 2014;111(7):2494–2499. doi:10.1073/pnas.1318962111.
- Wang X, Shi W, Shi H, Lu S, Wang K, Sun C, He J, Jin W, Lv X, Zou H, et al. TRIM11 overexpression promotes proliferation, migration and invasion of lung cancer cells. J Exp Clin Cancer Res. 2016;35(1):100. doi:10.1186/s13046-016-0379-y.
- Ahmad MK, Abdollah NA, Shafie NH, Yusof NM, Razak SRA. Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer. Cancer Biol Med. 2018;15:14–28. doi:10.20892/j.2095-3941.2017.0107.
- Okudela K, Yazawa T, Woo T, Sakaeda M, Ishii J, Mitsui H, Shimoyamada H, Sato H, Tajiri M, Ogawa N, et al. Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis. Am J Pathol. 2009;175(2):867–881. doi:10.2353/ajpath.2009.080489.
- Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol. 2003;162(6):1807–1815. doi:10.1016/S0002-9440(10)64315-5.
- Ji Q, Liu X, Han Z, Zhou L, Sui H, Yan L, Jiang H, Ren J, Cai J, Li Q. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-beta1/Smads signaling pathway mediated Snail/E-cadherin expression. BMC Cancer. 2015;15(1):97. doi:10.1186/s12885-015-1119-y.
- Sun H, Zhu A, Zhang L, Zhang J, Zhong Z, Wang F. Knockdown of PKM2 suppresses tumor growth and invasion in lung adenocarcinoma. Int J Mol Sci. 2015;16(10):24574–24587. doi:10.3390/ijms161024574.
- Liu Y, He C, Huang X. Metformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolism. Oncotarget. 2017;8(43):75206–75216. doi:10.18632/oncotarget.20663.
- Jing HZ, Qiu F, Chen SZ, Su L, Qu C. Tripartite-motif protein 25 and pyruvate kinase M2 protein expression in non-small cell lung cancer. Nan Fang Yi Ke Da Xue Xue Bao. 2015;35:437–441.
- Vicent S, Lopez-Picazo JM, Toledo G, Lozano MD, Torre W, Garcia-Corchon C, Quero C, Soria JC, Martin-Algarra S, Manzano RG, et al. ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer. 2004;90(5):1047–1052. doi:10.1038/sj.bjc.6601644.
- Wang J, Huang S. Fisetin inhibits the growth and migration in the A549 human lung cancer cell line via the ERK1/2 pathway. Exp Ther Med. 2018;15(3):2667–2673. doi:10.3892/etm.2017.5666.
- Zhang Z, Kobayashi S, Borczuk AC, Leidner RS, Laframboise T, Levine AD, Halmos B. Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis. 2010;31(4):577–586. doi:10.1093/carcin/bgq020.
- Xie XL, Nie X, Wu J, Zhang F, Zhao LL, Lin YL, Yin YJ, Liu H, Shu YN, Miao SB, et al. Smooth muscle 22alpha facilitates angiotensin II-induced signaling and vascular contraction. J Mol Med (Berl). 2015;93(5):547–558. doi:10.1007/s00109-014-1240-4.